Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p221b | Chondrocytes and cartilage | ECTS2016

Vitamin D supplementation for 12 months in older people prevents bone loss and suppresses parathyroid hormone levels

Aspray Terry J , Francis Roger M , McColl Elaine , Chadwick Thomas , Stamp Elaine , Prentice Ann , Schoenmakers Inez

Background, subjects and methods: Vitamin D insufficiency in older people in the UK is common and may cause secondary hyperparathyroidism and bone loss. In a randomised, double blind intervention trial to optimise “Vitamin D status in Older People’ (VDOP) three oral dosages of vitamin D3 (12 kIU, 24 kIU or 48 kIU/month) were given for 12 months to 375 participants aged over 70 years (ANOVA) adjustment for covariables with results below presented in ascendi...

ba0005p410 | Osteoporosis: treatment | ECTS2016

Can bone turnover markers help to define the duration of bisphosphonate drug holidays?

Statham Louise , Aspray Terry , Abdy Sharon

Background: On cessation of bisphosphonate treatment, while bone mineral density decreases slowly, bone resorptive markers such as C-terminal telopeptide (CTX) increase more quickly and may be useful in monitoring ‘offset’ of action. Our aim was to analyse changes in CTX on stopping long-term bisphosphonate treatment to guide clinical decision-making on the duration of treatment cessation (‘drug holidays’).Subjects and methods: A tota...

ba0001pp441 | Osteoporosis: treatment | ECTS2013

Reducing the risk of hypocalcaemia with parenteral antiresorptive therapies: an audit

Xu Wei , Baker Kenneth , Reavley Rachel , Oates Emily , Aspray Terry

Introduction: Intravenous bisphosphonates (IB) and subcutaneous denosumab (SD) are potent antiresorptive agents widely used in the treatment of osteoporosis, Paget’s disease and metastatic malignancy. Several case reports have identified the risk of life-threatening hypocalcaemia with these treatments, particularly in the context of vitamin D deficiency and further highlighted by recent UKMHRA advice.Design: To optimise vitamin D status and decrease...

ba0005lb11 | (1) | ECTS2016

25(OH)D3 half-life is not influenced by vitamin D supplementation dose

Schoenmakers Inez , Assar Shima , Aspray Terry , Prentice Ann , Jones Kerry

There is wide variation in the dose-response to oral vitamin D and the increment in plasma 25(OH)D decreases per unit vitamin D given. We hypothesised that this is related to increased 25(OH)D catabolism as reflected in 25OHD half-life (25(OH)D3 t1/2).Design: 25(OH)D3 t1/2 was measured with a stable isotope (SI) technique in older (70y+) men and women in the UK during winter before (<...

ba0001pp385 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Fracture risk assessment in a primary care population: case finding using routine GP data, FRAX® And RAIDR® in the United Kingdom

Aspray Terry , Whalley Erica , Scott Mike , Summers Steve , Turley Steve , Wright Rachel , Maddison Valerie , Abdy Sharon , Kay Lesley

Introduction: Fracture risk assessment using FRAX® estimates 10-year fracture risk (FR10) at major sites (Maj_FR10) and hip (Hip_FR10). In 2012, in Newcastle, UK, a strategy was agreed to share data between General Practice (GP), Clinical Commissioning Groups and local hospitals to identify patients at high FR10.Methods/design: FRAX® and RAID® (a health reporting, analysis and intelligence delive...

ba0001pp309 | Muscle, physical activity and bone | ECTS2013

Lean mass, not obesity, is related to total body bone mineral content in boys

Sanchez Tom , Wang Jingmei , Rajan Felix , Schwalenberg Terry , Dudzek Kathy

The literature has suggested that bone mineral content is modulated by muscle mass and activity. We investigated the relationship between DXA assessed total body bone mineral content, total body lean mass, appendicular lean mass and obesity (a possible marker of inactivity) in a population of 73 boys between the age of 7 and 19 using a Norland XR-46 system.Regression analysis shows that in these growing boys there is a strong positive relationship betwee...

ba0002p163 | (1) | ICCBH2013

Phenotype–genotype correlation and role of ancillary investigations in atypical and rare forms of osteogenesis imperfecta

Balasubramanian Meena , Parker Michael , Bishop Nicholas J

Background: Osteogenesis imperfecta (OI) is a heterogeneous group of inherited disorders of bone formation, resulting in low bone mass and an increased propensity to fracture. It is a variable condition with a range of clinical severity. About 90% of patients with a clinical diagnosis of OI have a mutation in the COL1A1 or COL1A2 genes, which shows an autosomal dominant pattern (AD) of inheritance. Other genes are associated with the autosomal recessive (AR) ...